Eli Lilly and Company to Acquire Ventyx Biosciences

Eli Lilly Acquires Versanis Bio

July 14, 2023

Biotechnology

Eli Lilly has entered into a definitive agreement to acquire Versanis Bio, a private clinical-stage biopharmaceutical company developing bimagrumab for cardiometabolic diseases and obesity. The deal could deliver up to $1.925 billion to Versanis shareholders and is intended to combine Versanis’ activin/myostatin biology expertise with Lilly’s incretin portfolio to advance combination treatments for obesity and related cardiometabolic conditions.

Eli Lilly Acquires Verve Therapeutics

July 25, 2025

Biotechnology

Eli Lilly and Company completed the acquisition of Verve Therapeutics, a Boston-based clinical-stage developer of one-time gene-editing therapies for cardiovascular disease. Lilly said the deal will integrate Verve's genetic-medicine programs into its cardiometabolic research to advance potential lifelong cardiovascular risk–reduction treatments.

Sanofi to Acquire Vicebio for Up to $1.6 Billion

July 25, 2025

Healthcare Services

Sanofi has entered an exclusive, definitive agreement to acquire biopharmaceutical company Vicebio for up to US$1.6 billion, comprising a US$1.15 billion upfront payment plus up to US$450 million in development and regulatory milestones. The deal is aimed at accelerating Vicebio’s next-generation respiratory virus vaccine platform, including lead candidate VXB-241 targeting RSV and hMPV.

Eli Lilly Acquires Adverum Biotechnologies

December 9, 2025

Biotechnology

Eli Lilly and Company agreed to acquire Adverum Biotechnologies in a cash-and-contingent-value-rights tender offer for all outstanding shares. The total consideration is $3.56 per share in cash at closing plus a CVR that could pay up to $8.91 per share upon achievement of specified milestones, with the transaction expected to close in the fourth quarter of 2025.

BioVie Acquires Biopharma Assets of NeurMedix

June 11, 2021

Pharmaceuticals

BioVie Inc. acquired the biopharmaceutical assets of privately held NeurMedix, including NE3107, an orally administered small-molecule inhibitor targeting neuroinflammation and insulin resistance. The deal paid NeurMedix shareholders newly issued BioVie shares and cash at closing, with additional contingent cash and equity payments tied to clinical and regulatory milestones; the acquisition expands BioVie's pipeline into neurodegenerative diseases and oncology.

AbbVie Completes Acquisition of Landos Biopharma

May 23, 2024

Pharmaceuticals

AbbVie completed its acquisition of clinical-stage biopharmaceutical company Landos Biopharma for $20.42 per share in cash, plus a contingent value right (CVR) tied to a clinical milestone. The deal adds Landos’ first-in-class investigational asset NX-13 to AbbVie’s immunology pipeline for potential treatment of ulcerative colitis and Crohn’s disease.